BioWorld

Nov. 25, 2002

Myriad Genetics Raises $57.3M Through Stock Sale From Shelf

About two weeks after filing a shelf registration statement to sell up to $250 million in securities, Myriad Genetics Inc. is raising $57.3 million through a pursuant offering of 3 million shares of stock. (BioWorld Today) Read More

Altea Series B Raises $17M For Trials Of Lead Products

Vaccine Against Cervical Cancer Racked Up 100 Percent Efficacy In Placebo-Controlled Human Trial

From 'Position Of Strength,' QLT Reduces Staff 18 Percent

Other News To Note

Appointments And Announcements

Correction

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...